DMC Biotechnologies raises $18 million to expand health ingredients business

DMC Biotechnologies secured $18 million in financing to speed commercialization of its KeyPura™ ingredients and expand into health, wellness and personal care markets. The Morrisville, North Carolina company will use the funding to grow customer adoption, add new bioactive ingredients and deepen its distribution reach.

Why it matters: - The new capital gives DMC Biotechnologies more room to scale a precision-fermentation platform in the health ingredients market. - The financing is aimed at commercial growth, not just research, which can speed market adoption of DMC’s existing products and future ingredients. - The company is targeting markets where purity, consistency, traceability and reliable supply matter to formulators.

What happened: - DMC Biotechnologies announced it secured $18 million in financing on Oct. 26, 2026. - Inceptional Partners and Sofinnova Partners co-led the round. - First Bight Ventures participated, along with existing investors Cibus Capital and Capricorn Partners. - DMC is based in Morrisville, North Carolina.

The details: - DMC develops high-purity, science-backed bioactives through precision fermentation. - The company’s KeyPura™ portfolio includes myo-inositol and D-chiro-inositol. - Those ingredients are used in reproductive health, metabolic wellness, infant nutrition and other specialty nutrition formulations. - DMC says KeyPura™ ingredients are produced through precision fermentation and offer a differentiated approach to ingredient quality and production. - The financing will help DMC expand adoption of its commercial products and advance additional bioactive ingredients. - DMC plans to direct the funding toward continued commercialization of its current portfolio and development of future health and wellness ingredients. - DMC also wants to strengthen customer and distribution relationships. - DMC’s approach combines proprietary biotechnology with a market-driven commercialization strategy. - The company says its platform supports scalable production and flexibility across the broader health ingredients market. - The company’s website is More information.

Between the lines: - The round signals investor confidence in DMC’s ability to turn a fermentation platform into commercial ingredient sales. - The focus on existing products suggests DMC is entering a scale-up phase rather than a pure R&D phase. - Board member Andras Forgacs said the company has built a differentiated technology platform with meaningful market potential and is positioned for its next phase of commercial growth. - Chief Executive Officer Jim Flatt said DMC is now focused on translating its production capability into broader market adoption, new products and long-term commercial growth.

What's next: - DMC expects to use the money to accelerate commercialization of KeyPura™ ingredients. - The company plans to keep expanding its portfolio with new health and wellness ingredients. - Broader customer adoption and deeper market penetration across health, wellness and personal care are the next priorities.

The bottom line: - DMC has fresh funding to push its precision-fermentation ingredients from launch into wider commercial use.